TEICOPLANIN

Teicoplanin Adverse Events Reported to the FDA Over Time

How are Teicoplanin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Teicoplanin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Teicoplanin is flagged as the suspect drug causing the adverse event.

Most Common Teicoplanin Adverse Events Reported to the FDA

What are the most common Teicoplanin adverse events reported to the FDA?

Pyrexia	36 (2.73%)
Thrombocytopenia	36 (2.73%)
Drug Interaction	21 (1.59%)
Hyphaema	20 (1.51%)
Septic Shock	20 (1.51%)
Neutropenia	19 (1.44%)
Blood Bilirubin Increased	18 (1.36%)
International Normalised Ratio Incr...	18 (1.36%)
Neutropenic Sepsis	18 (1.36%)
Intraocular Pressure Increased	16 (1.21%)
Toxic Epidermal Necrolysis	16 (1.21%)
	Show More
Clostridium Difficile Colitis	14 (1.06%)
Drug Ineffective	14 (1.06%)
Erythema	14 (1.06%)
Nausea	14 (1.06%)
Respiratory Failure	14 (1.06%)
Anaphylactic Reaction	13 (.98%)
Death	13 (.98%)
Headache	13 (.98%)
Renal Failure	13 (.98%)
Staphylococcal Infection	13 (.98%)
Alanine Aminotransferase Increased	12 (.91%)
Anaemia	12 (.91%)
Aspartate Aminotransferase Increase...	12 (.91%)
Renal Failure Acute	12 (.91%)
Sepsis	12 (.91%)
Eosinophilia	11 (.83%)
Hepatic Failure	11 (.83%)
Leukopenia	11 (.83%)
Multi-organ Failure	11 (.83%)
Platelet Count Decreased	11 (.83%)
Rash	11 (.83%)
Agranulocytosis	10 (.76%)
Condition Aggravated	10 (.76%)
Decreased Appetite	10 (.76%)
Febrile Neutropenia	10 (.76%)
Hallucination, Visual	10 (.76%)
Skin Exfoliation	10 (.76%)
Cardiac Failure	9 (.68%)
Hepatic Function Abnormal	9 (.68%)
White Blood Cell Count Decreased	9 (.68%)
Confusional State	8 (.61%)
Diarrhoea	8 (.61%)
Eye Pain	8 (.61%)
General Physical Health Deteriorati...	8 (.61%)
Pancytopenia	8 (.61%)
Renal Impairment	8 (.61%)
Stevens-johnson Syndrome	8 (.61%)
Cardiac Arrest	7 (.53%)
Cardio-respiratory Arrest	7 (.53%)
Dyspnoea	7 (.53%)
Hepatotoxicity	7 (.53%)
Pleural Effusion	7 (.53%)
Pneumonia	7 (.53%)
Staphylococcal Sepsis	7 (.53%)
Cellulitis	6 (.45%)
Disseminated Intravascular Coagulat...	6 (.45%)
Gamma-glutamyltransferase Increased	6 (.45%)
Haemodialysis	6 (.45%)
Hepatic Enzyme Increased	6 (.45%)
Intestinal Perforation	6 (.45%)
Liver Injury	6 (.45%)
Purpura	6 (.45%)
Bronchopulmonary Aspergillosis	5 (.38%)
Candidiasis	5 (.38%)
Convulsion	5 (.38%)
Drug Resistance	5 (.38%)
Haemoglobin Decreased	5 (.38%)
Hypotension	5 (.38%)
Liver Disorder	5 (.38%)
Mycobacterium Fortuitum Infection	5 (.38%)
Rash Maculo-papular	5 (.38%)
Vomiting	5 (.38%)
Cardiac Failure Congestive	4 (.3%)
Chalazion	4 (.3%)
Coagulation Time Prolonged	4 (.3%)
Dermatitis Exfoliative	4 (.3%)
Drug Rash With Eosinophilia And Sys...	4 (.3%)
Haemoptysis	4 (.3%)
Hyperglycaemia	4 (.3%)
Influenza	4 (.3%)
Leukocytosis	4 (.3%)
Lymphangitis	4 (.3%)
Metabolic Acidosis	4 (.3%)
Oral Mucosa Erosion	4 (.3%)
Pseudomonas Infection	4 (.3%)
Rash Generalised	4 (.3%)
Rash Scarlatiniform	4 (.3%)
Renal Failure Chronic	4 (.3%)
Respiratory Distress	4 (.3%)
Acute Myeloid Leukaemia	3 (.23%)
Ascites	3 (.23%)
Aspergillosis	3 (.23%)
Blood Alkaline Phosphatase Increase...	3 (.23%)
C-reactive Protein Increased	3 (.23%)
Cheilitis	3 (.23%)
Chills	3 (.23%)
Device Related Infection	3 (.23%)
Diabetic Retinopathy	3 (.23%)
Drug Hypersensitivity	3 (.23%)
Drug Ineffective For Unapproved Ind...	3 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Teicoplanin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Teicoplanin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Teicoplanin

What are the most common Teicoplanin adverse events reported to the FDA?

Epidermal And Dermal Conditions	98 (7.42%)
Infections - Pathogen Unspecified	90 (6.81%)
Hematology Investigations	74 (5.6%)
White Blood Cell	69 (5.22%)
Bacterial Infectious	66 (5%)
Hepatic And Hepatobiliary	61 (4.62%)
Hepatobiliary	56 (4.24%)
Therapeutic And Nontherapeutic Effe...	52 (3.94%)
Renal Disorders	41 (3.1%)
Body Temperature Conditions	39 (2.95%)
Platelet	39 (2.95%)
	Show More
Respiratory	39 (2.95%)
Cardiac Arrhythmias	24 (1.82%)
Gastrointestinal Signs	24 (1.82%)
Ocular Hemorrhages And Vascular	21 (1.59%)
Anemias Nonhemolytic And Marrow Dep...	20 (1.51%)
Fungal Infectious	19 (1.44%)
Allergic Conditions	18 (1.36%)
Heart Failures	16 (1.21%)
Neurological	16 (1.21%)
Neurological, Special Senses And Ps...	16 (1.21%)
Fatal Outcomes	13 (.98%)
Headaches	13 (.98%)
Gastrointestinal Motility And Defec...	11 (.83%)
Appetite And General Nutritional	10 (.76%)
Disturbances In Thinking	10 (.76%)
Lower Respiratory Tract Disorders	10 (.76%)
Hematological And Lymphoid Tissue T...	9 (.68%)
Ocular Infections, Irritations And ...	9 (.68%)
Oral Soft Tissue Conditions	9 (.68%)
Viral Infectious	9 (.68%)
Vision	9 (.68%)
Deliria	8 (.61%)
Eye	8 (.61%)
Gastrointestinal Ulceration And Per...	8 (.61%)
Cardiac And Vascular Investigations	7 (.53%)
Coagulopathies And Bleeding Diathes...	7 (.53%)
Decreased And Nonspecific Blood Pre...	7 (.53%)
Electrolyte And Fluid Balance Condi...	7 (.53%)
Gastrointestinal Hemorrhages	7 (.53%)
Pleural	7 (.53%)
Procedural And Device Related Injur...	7 (.53%)
Seizures	7 (.53%)
Skin Vascular Abnormalities	7 (.53%)
Acid-base	6 (.45%)
Immune	6 (.45%)
Peritoneal And Retroperitoneal Cond...	6 (.45%)
Central Nervous System Vascular	5 (.38%)
Encephalopathies	5 (.38%)
Enzyme	5 (.38%)
Glucose Metabolism Disorders	5 (.38%)
Mycobacterial Infectious	5 (.38%)
Nephropathies	5 (.38%)
Sleep Disorders	5 (.38%)
Administration Site Reactions	4 (.3%)
Angiedema And Urticaria	4 (.3%)
Anxiety Disorders	4 (.3%)
Bone And Joint Injuries	4 (.3%)
Gastrointestinal Inflammatory Condi...	4 (.3%)
Leukemias	4 (.3%)
Protein And Chemistry Analyses	4 (.3%)
Ancillary Infectious Topics	3 (.23%)
Cardiac Valve	3 (.23%)
Gastrointestinal Vascular Condition...	3 (.23%)
Injuries	3 (.23%)
Microbiology And Serology	3 (.23%)
Musculoskeletal And Connective Tiss...	3 (.23%)
Myocardial	3 (.23%)
Ocular Neuromuscular	3 (.23%)
Physical Examination Topics	3 (.23%)
Retina, Choroid And Vitreous Hemorr...	3 (.23%)
Toxicology And Therapeutic Drug Mon...	3 (.23%)
Vascular Inflammations	3 (.23%)
Bronchial Disorders	2 (.15%)
Chemical Injury And Poisoning	2 (.15%)
Dissociative	2 (.15%)
Eye Therapeutic Procedures	2 (.15%)
Hemolyses And Related Conditions	2 (.15%)
Immunology And Allergy	2 (.15%)
Neonatal Respiratory	2 (.15%)
Pericardial	2 (.15%)
Pulmonary Vascular	2 (.15%)
Skin And Subcutaneous Tissue	2 (.15%)
Vascular	2 (.15%)
Vascular Hypertensive	2 (.15%)
Water, Electrolyte And Mineral	2 (.15%)
Cardiac And Vascular Disorders Cong...	1 (.08%)
Coronary Artery	1 (.08%)
Cranial Nerve Disorders	1 (.08%)
Exocrine Pancreas Conditions	1 (.08%)
Gastrointestinal Neoplasms Malignan...	1 (.08%)
Hematopoietic Neoplasms	1 (.08%)
Hepatobiliary Neoplasms Malignant A...	1 (.08%)
Hepatobiliary Therapeutic Procedure...	1 (.08%)
Increased Intracranial Pressure And...	1 (.08%)
Inner Ear And Viiith Cranial Nerve	1 (.08%)
Lymphomas Non-hodgkins B-cell	1 (.08%)
Medication Errors	1 (.08%)
Miscellaneous And Site Unspecified ...	1 (.08%)
Movement Disorders	1 (.08%)
Muscle	1 (.08%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Teicoplanin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Teicoplanin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.